Clinical Edge Journal Scan

Pro-Vegetarian Diet May Lower Risk for Breast Cancer


 

Key clinical point: The pro-vegetarian dietary pattern (PDP) was associated with a significantly lower risk for breast cancer (BC) in women, particularly postmenopausal women.

Major finding: Compared with women who had low adherence to PDP (score ≤ 33), the risk for BC was significantly lower among women with moderate adherence to PDP (score 34-38; adjusted odds ratio [aOR] 0.42; P = .003) and in those with high adherence to PDP (score ≥ 39; aOR 0.49; P = .017), with outcomes being similar in the subgroup of postmenopausal women.

Study details: Findings are from a case-control study including women with BC (n = 134) and those without cancer (n = 265).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Hosseini Y, Hadi Sichani P, Moslemi E, et al. Pro-vegetarian dietary pattern and risk of breast cancer: A case-control study. Breast Cancer Res Treat. 2024 (Feb 28). doi: 10.1007/s10549-024-07243-8 Source

Recommended Reading

ASTRO Pushes Return to Direct Supervision in RT: Needed or ‘Babysitting’?
MDedge Hematology and Oncology
Look Beyond BMI: Metabolic Factors’ Link to Cancer Explained
MDedge Hematology and Oncology
MRI Surveillance Reduces Breast Cancer Mortality in Women with BRCA1 Sequence Variation
MDedge Hematology and Oncology
Hyperbaric Oxygenation May Reduce Late Local Toxic Effects After Breast Cancer Irradiation
MDedge Hematology and Oncology
Enobosarm Shows Antitumor Activity in ER+ Advanced BC in Phase 2
MDedge Hematology and Oncology
Doxorubicin May Raise Breast Cancer Risk in Hodgkin Lymphoma Survivors
MDedge Hematology and Oncology
Breast-Conserving Surgery Does Not Increase Locoregional Recurrence in TNBC
MDedge Hematology and Oncology
Obesity and Family History of Cancer Raise Breast Cancer Risk
MDedge Hematology and Oncology
Axillary Lymph Node Dissection Can Be Safely Skipped in Breast Cancer Patients Undergoing Mastectomy
MDedge Hematology and Oncology
Real-World Study Supports Everolimus + Exemestane as HR+/HER2− BC Treatment
MDedge Hematology and Oncology